These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 9436820)
1. Phosphodiesterases in the rat renal vasculature. Jackson EK; Mi Z; Carcillo JA; Gillespie DG; Dubey RK J Cardiovasc Pharmacol; 1997 Dec; 30(6):798-801. PubMed ID: 9436820 [TBL] [Abstract][Full Text] [Related]
2. Characterization of renal ecto-phosphodiesterase. Jackson EK; Ren J; Zacharia LC; Mi Z J Pharmacol Exp Ther; 2007 May; 321(2):810-5. PubMed ID: 17308037 [TBL] [Abstract][Full Text] [Related]
3. Regulation of renovascular adenosine 3',5'-cyclic monophosphate in spontaneously hypertensive rats. Jackson EK; Mi Z Hypertension; 2009 Aug; 54(2):270-7. PubMed ID: 19528365 [TBL] [Abstract][Full Text] [Related]
4. Regulation of 3',5'-cAMP in preglomerular smooth muscle and endothelial cells from genetically hypertensive rats. Cheng D; Ren J; Gillespie DG; Mi Z; Jackson EK Hypertension; 2010 Dec; 56(6):1096-101. PubMed ID: 20975032 [TBL] [Abstract][Full Text] [Related]
5. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells. Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650 [TBL] [Abstract][Full Text] [Related]
6. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine. Katano Y; Endoh M J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732 [TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Pan X; Arauz E; Krzanowski JJ; Fitzpatrick DF; Polson JB Biochem Pharmacol; 1994 Aug; 48(4):827-35. PubMed ID: 7521642 [TBL] [Abstract][Full Text] [Related]
8. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes. Elks ML; Manganiello VC Endocrinology; 1984 Oct; 115(4):1262-8. PubMed ID: 6207009 [TBL] [Abstract][Full Text] [Related]
9. Two mechanisms of inhibition by prostaglandin E2 of hormone-dependent cell cAMP in the rat collecting tubule. Chabardès D; Montégut M; Zhou Y; Siaume-Perez S Mol Cell Endocrinol; 1990 Oct; 73(2-3):111-21. PubMed ID: 1702742 [TBL] [Abstract][Full Text] [Related]
10. Differential effects of phosphodiesterase inhibitors on accumulation of cyclic AMP in isolated ventricular cardiomyocytes. Kelso EJ; McDermott BJ; Silke B Biochem Pharmacol; 1995 Feb; 49(4):441-52. PubMed ID: 7872950 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. Derian CK; Santulli RJ; Rao PE; Solomon HF; Barrett JA J Immunol; 1995 Jan; 154(1):308-17. PubMed ID: 7995950 [TBL] [Abstract][Full Text] [Related]
12. Regulation of isoproterenol-induced cyclic AMP accumulation in LRM55 glial cells by phosphodiesterase. Madelian V; Shain W J Pharmacol Exp Ther; 1987 Nov; 243(2):618-23. PubMed ID: 2445955 [TBL] [Abstract][Full Text] [Related]
13. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism. Zhu WH; Majluf-Cruz A; Omburo GA Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035 [TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Wright CD; Kuipers PJ; Kobylarz-Singer D; Devall LJ; Klinkefus BA; Weishaar RE Biochem Pharmacol; 1990 Aug; 40(4):699-707. PubMed ID: 1696820 [TBL] [Abstract][Full Text] [Related]
15. Evidence for an endogenous cAMP-adenosine pathway in the rat kidney. Mi Z; Jackson EK J Pharmacol Exp Ther; 1998 Dec; 287(3):926-30. PubMed ID: 9864274 [TBL] [Abstract][Full Text] [Related]
16. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. Nielson CP; Vestal RE; Sturm RJ; Heaslip R J Allergy Clin Immunol; 1990 Nov; 86(5):801-8. PubMed ID: 1977788 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts. Bethke T; Klimkiewicz A; Meyer W; Schumacher C; Schmitz W; Scholz H; Starbatty J; Wenzlaff H; Zimmermann W Arzneimittelforschung; 1995 Jul; 45(7):771-6. PubMed ID: 8573220 [TBL] [Abstract][Full Text] [Related]
19. Metabolism of cAMP to adenosine in the renal vasculature. Jackson EK; Mi Z; Gillespie DG; Dubey RK J Pharmacol Exp Ther; 1997 Oct; 283(1):177-82. PubMed ID: 9336322 [TBL] [Abstract][Full Text] [Related]
20. The role of phosphodiesterase in mediating the effect of protein kinase C on cyclic AMP accumulation upon kappa-opioid receptor stimulation in the rat heart. Bian JS; Zhang WM; Pei JM; Wong TM J Pharmacol Exp Ther; 2000 Mar; 292(3):1065-70. PubMed ID: 10688624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]